Menu
GWAS Study

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.

Kiiskinen T, Helkkula P, Krebs K et al.

36653479 PubMed ID
GWAS Study Type
567671 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KT
Kiiskinen T
HP
Helkkula P
KK
Krebs K
KJ
Karjalainen J
SE
Saarentaus E
MN
Mars N
LA
Lehisto A
ZW
Zhou W
CM
Cordioli M
JS
Jukarainen S
RJ
Rämö JT
MJ
Mehtonen J
VK
Veerapen K
RM
Räsänen M
RS
Ruotsalainen S
MM
Maasha M
NT
Niiranen T
TT
Tuomi T
SV
Salomaa V
KM
Kurki M
PM
Pirinen M
PA
Palotie A
DM
Daly M
GA
Ganna A
HA
Havulinna AS
ML
Milani L
RS
Ripatti S
Chapter II

Abstract

Summary of the research findings

Little is known about the genetic determinants of medication use in preventing cardiometabolic diseases. Using the Finnish nationwide drug purchase registry with follow-up since 1995, we performed genome-wide association analyses of longitudinal patterns of medication use in hyperlipidemia, hypertension and type 2 diabetes in up to 193,933 individuals (55% women) in the FinnGen study. In meta-analyses of up to 567,671 individuals combining FinnGen with the Estonian Biobank and the UK Biobank, we discovered 333 independent loci (P < 5 × 10-9) associated with medication use. Fine-mapping revealed 494 95% credible sets associated with the total number of medication purchases, changes in medication combinations or treatment discontinuation, including 46 credible sets in 40 loci not associated with the underlying treatment targets. The polygenic risk scores (PRS) for cardiometabolic risk factors were strongly associated with the medication-use behavior. A medication-use enhanced multitrait PRS for coronary artery disease matched the performance of a risk factor-based multitrait coronary artery disease PRS in an independent sample (UK Biobank, n = 343,676). In summary, we demonstrate medication-based strategies for identifying cardiometabolic risk loci and provide genome-wide tools for preventing cardiovascular diseases.

567,671 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

567671
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.